<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Integrated Network Disruption Theory of Alzheimer's Disease - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-2356</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-2356</p>
                <p><strong>Name:</strong> Integrated Network Disruption Theory of Alzheimer's Disease</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of the causes of Alzheimer's disease and effective detection methods.</p>
                <p><strong>Description:</strong> This theory posits that Alzheimer's disease (AD) arises from the convergence of multiple, interacting disruptions in neural, vascular, immune, and metabolic networks, rather than from a single pathological trigger. The interplay between amyloid-beta, tau, neuroinflammation, vascular dysfunction, and metabolic impairment leads to a self-reinforcing cascade that ultimately results in neurodegeneration and cognitive decline. Effective detection must therefore target network-level biomarkers and multi-modal signatures rather than single-molecule markers.</p>
                <p><strong>Knowledge Cutoff Year:</strong> -1</p>
                <p><strong>Knowledge Cutoff Month:</strong> -1</p>
                <p><strong>Base Model:</strong> openai/gpt-4.1-2025-04-14</p>
            </div>
        </div>

        <div class="section">
            <h2>Theory (Derived From)</h2>
            <p><strong>Derived From:</strong> <span class="empty-note">None</span></p>
            <p><strong>Change Log:</strong> <span class="empty-note">No change log entries.</span></p>
        </div>

        <div class="section">
            <h2>Evaluations of this Theory</h2>
            <p class="empty-note">No evaluations of this theory.</p>
        </div>

        <div class="section">
            <h2>Theory (Details)</h2>

            <h3>Theory Statements</h3>
            <h3>Statement 0: Network Cascade Law (qualitative)</h3>
<table>
<thead> 
<tr><th style="width: 10%;">Condition</th><th style="width: 90%;">Details</th></tr>
</thead>
<tbody>
<tr>
    <td><strong>IF</strong></td>
    <td>
        <div>&#8226; brain &#8594; exhibits &#8594; concurrent disruptions in amyloid, tau, vascular, immune, and metabolic systems</div>
    </td>
</tr>
<tr>
    <td><strong>THEN</strong></td>
    <td>
        <div>&#8226; brain &#8594; undergoes &#8594; self-reinforcing neurodegenerative cascade<span style="color: #888888;">, and</span></div>
        <div>&#8226; individual &#8594; develops &#8594; progressive cognitive decline</div>
    </td>
</tr>
</tbody>
</table>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>AD brains show co-occurrence of amyloid plaques, tau tangles, neuroinflammation, vascular pathology, and metabolic dysfunction. </li>
    <li>Longitudinal studies show that these pathologies interact and accelerate each other's progression. </li>
    <li>Network-based analyses reveal that disruptions in one domain (e.g., vascular) can exacerbate others (e.g., amyloid accumulation, neuroinflammation). </li>
    <li>Therapeutic interventions targeting only one domain (e.g., anti-amyloid) have limited efficacy, suggesting multi-domain involvement. </li>
    <li>Metabolic impairment (e.g., glucose hypometabolism) is observed early and correlates with other pathologies. </li>
</ol>            <h4>Existing Law Comparison</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
            <p><strong>Explanation:</strong> While multi-factorial models exist, this law's explicit requirement for network-level, self-reinforcing interactions is a novel synthesis.</p>            <p><strong>What Already Exists:</strong> Existing theories recognize the roles of amyloid, tau, and neuroinflammation, and some acknowledge vascular and metabolic contributions.</p>            <p><strong>What is Novel:</strong> This law formalizes the necessity of concurrent, interacting disruptions across multiple systems as the primary driver, rather than any single pathology.</p>
            <p><strong>References:</strong> <ul>
    <li>De Strooper & Karran (2016) The Cellular Phase of Alzheimer's Disease [Reviews multi-factorial pathogenesis]</li>
    <li>Iturria-Medina et al. (2016) Multifactorial causal model of brain (dis)organization and therapeutic intervention: Application to Alzheimer's disease [Network-level modeling]</li>
    <li>Jack et al. (2018) NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease [Biomarker-based, but not network-centric]</li>
</ul>
            <h3>Statement 1: Multi-Modal Detection Law (qualitative)</h3>
<table>
<thead> 
<tr><th style="width: 10%;">Condition</th><th style="width: 90%;">Details</th></tr>
</thead>
<tbody>
<tr>
    <td><strong>IF</strong></td>
    <td>
        <div>&#8226; detection_method &#8594; integrates &#8594; biomarkers from neural, vascular, immune, and metabolic domains</div>
    </td>
</tr>
<tr>
    <td><strong>THEN</strong></td>
    <td>
        <div>&#8226; detection_method &#8594; achieves &#8594; higher sensitivity and specificity for early AD diagnosis</div>
    </td>
</tr>
</tbody>
</table>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Single-modality biomarkers (e.g., amyloid PET) have limited predictive value; multi-modal approaches improve diagnostic accuracy. </li>
    <li>Recent machine learning models using multi-omic and imaging data outperform single-biomarker approaches. </li>
    <li>Blood-based, imaging, and CSF markers from different domains provide complementary information. </li>
    <li>Early detection is improved when combining vascular, metabolic, and neuroinflammatory markers with classical amyloid/tau measures. </li>
</ol>            <h4>Existing Law Comparison</h4>
            <p><strong>Likely Classification:</strong> closely-related-to-existing</p>
            <p><strong>Explanation:</strong> The law's emphasis on network-level integration and necessity for early detection is a novel extension of current practice.</p>            <p><strong>What Already Exists:</strong> Multi-modal biomarker approaches are increasingly used in research and some clinical settings.</p>            <p><strong>What is Novel:</strong> This law asserts that only integrated, network-level biomarker panels can reliably detect AD in its earliest stages.</p>
            <p><strong>References:</strong> <ul>
    <li>Hampel et al. (2018) Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic [Multi-modal biomarker review]</li>
    <li>Iturria-Medina et al. (2017) Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis [Multi-modal detection]</li>
    <li>Jack et al. (2018) NIA-AA Research Framework [Multi-modal, but not network-centric]</li>
</ul>
            <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>Individuals with early, subclinical disruptions in at least three of the five major domains (amyloid, tau, vascular, immune, metabolic) will progress to AD at higher rates than those with isolated pathology.</li>
                <li>Multi-modal biomarker panels (combining imaging, blood, and CSF markers) will outperform any single biomarker in predicting conversion from mild cognitive impairment to AD.</li>
                <li>Network-level interventions (e.g., lifestyle changes affecting vascular and metabolic health) will slow progression more than single-target drugs.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>Interventions that simultaneously target multiple disrupted networks (e.g., anti-amyloid, anti-inflammatory, vascular support, metabolic enhancement) will halt or reverse early AD progression more effectively than single-target therapies.</li>
                <li>Novel network-level biomarkers (e.g., connectome-based signatures) will enable pre-symptomatic detection of AD decades before clinical onset.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>If individuals with only one disrupted domain (e.g., amyloid only) progress to AD at the same rate as those with multi-domain disruption, the theory is challenged.</li>
                <li>If single-modality detection methods are found to be as accurate as multi-modal approaches in large, diverse cohorts, the theory is called into question.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>Rare familial AD cases with single-gene mutations may not require multi-domain disruption. </li>
</ol>            <h3>Existing Theory Comparison</h3>
            <p><strong>Likely Classification:</strong> somewhat-related-to-existing</p>
            <p><strong>Explanation:</strong> This theory builds on and extends existing multi-factorial models by formalizing the necessity of network-level, self-reinforcing interactions and detection.</p>
            <p><strong>References:</strong> <ul>
    <li>De Strooper & Karran (2016) The Cellular Phase of Alzheimer's Disease [Multi-factorial pathogenesis]</li>
    <li>Iturria-Medina et al. (2016) Multifactorial causal model of brain (dis)organization and therapeutic intervention: Application to Alzheimer's disease [Network-level modeling]</li>
    <li>Jack et al. (2018) NIA-AA Research Framework [Multi-modal biomarker approach]</li>
</ul>
        </div>

        <div class="section">
            <h2>Theory Components (Debug)</h2>
            <pre><code>{
    "theory_name": "Integrated Network Disruption Theory of Alzheimer's Disease",
    "theory_description": "This theory posits that Alzheimer's disease (AD) arises from the convergence of multiple, interacting disruptions in neural, vascular, immune, and metabolic networks, rather than from a single pathological trigger. The interplay between amyloid-beta, tau, neuroinflammation, vascular dysfunction, and metabolic impairment leads to a self-reinforcing cascade that ultimately results in neurodegeneration and cognitive decline. Effective detection must therefore target network-level biomarkers and multi-modal signatures rather than single-molecule markers.",
    "theory_statements": [
        {
            "law": {
                "law_name": "Network Cascade Law",
                "if": [
                    {
                        "subject": "brain",
                        "relation": "exhibits",
                        "object": "concurrent disruptions in amyloid, tau, vascular, immune, and metabolic systems"
                    }
                ],
                "then": [
                    {
                        "subject": "brain",
                        "relation": "undergoes",
                        "object": "self-reinforcing neurodegenerative cascade"
                    },
                    {
                        "subject": "individual",
                        "relation": "develops",
                        "object": "progressive cognitive decline"
                    }
                ],
                "supporting_evidence": [
                    {
                        "text": "AD brains show co-occurrence of amyloid plaques, tau tangles, neuroinflammation, vascular pathology, and metabolic dysfunction.",
                        "uuids": []
                    },
                    {
                        "text": "Longitudinal studies show that these pathologies interact and accelerate each other's progression.",
                        "uuids": []
                    },
                    {
                        "text": "Network-based analyses reveal that disruptions in one domain (e.g., vascular) can exacerbate others (e.g., amyloid accumulation, neuroinflammation).",
                        "uuids": []
                    },
                    {
                        "text": "Therapeutic interventions targeting only one domain (e.g., anti-amyloid) have limited efficacy, suggesting multi-domain involvement.",
                        "uuids": []
                    },
                    {
                        "text": "Metabolic impairment (e.g., glucose hypometabolism) is observed early and correlates with other pathologies.",
                        "uuids": []
                    }
                ],
                "qual_or_quant": "qualitative",
                "existing_law": {
                    "what_already_exists": "Existing theories recognize the roles of amyloid, tau, and neuroinflammation, and some acknowledge vascular and metabolic contributions.",
                    "what_is_novel": "This law formalizes the necessity of concurrent, interacting disruptions across multiple systems as the primary driver, rather than any single pathology.",
                    "classification_explanation": "While multi-factorial models exist, this law's explicit requirement for network-level, self-reinforcing interactions is a novel synthesis.",
                    "likely_classification": "somewhat-related-to-existing",
                    "references": [
                        "De Strooper & Karran (2016) The Cellular Phase of Alzheimer's Disease [Reviews multi-factorial pathogenesis]",
                        "Iturria-Medina et al. (2016) Multifactorial causal model of brain (dis)organization and therapeutic intervention: Application to Alzheimer's disease [Network-level modeling]",
                        "Jack et al. (2018) NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease [Biomarker-based, but not network-centric]"
                    ]
                }
            }
        },
        {
            "law": {
                "law_name": "Multi-Modal Detection Law",
                "if": [
                    {
                        "subject": "detection_method",
                        "relation": "integrates",
                        "object": "biomarkers from neural, vascular, immune, and metabolic domains"
                    }
                ],
                "then": [
                    {
                        "subject": "detection_method",
                        "relation": "achieves",
                        "object": "higher sensitivity and specificity for early AD diagnosis"
                    }
                ],
                "supporting_evidence": [
                    {
                        "text": "Single-modality biomarkers (e.g., amyloid PET) have limited predictive value; multi-modal approaches improve diagnostic accuracy.",
                        "uuids": []
                    },
                    {
                        "text": "Recent machine learning models using multi-omic and imaging data outperform single-biomarker approaches.",
                        "uuids": []
                    },
                    {
                        "text": "Blood-based, imaging, and CSF markers from different domains provide complementary information.",
                        "uuids": []
                    },
                    {
                        "text": "Early detection is improved when combining vascular, metabolic, and neuroinflammatory markers with classical amyloid/tau measures.",
                        "uuids": []
                    }
                ],
                "qual_or_quant": "qualitative",
                "existing_law": {
                    "what_already_exists": "Multi-modal biomarker approaches are increasingly used in research and some clinical settings.",
                    "what_is_novel": "This law asserts that only integrated, network-level biomarker panels can reliably detect AD in its earliest stages.",
                    "classification_explanation": "The law's emphasis on network-level integration and necessity for early detection is a novel extension of current practice.",
                    "likely_classification": "closely-related-to-existing",
                    "references": [
                        "Hampel et al. (2018) Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic [Multi-modal biomarker review]",
                        "Iturria-Medina et al. (2017) Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis [Multi-modal detection]",
                        "Jack et al. (2018) NIA-AA Research Framework [Multi-modal, but not network-centric]"
                    ]
                }
            }
        }
    ],
    "new_predictions_likely": [
        "Individuals with early, subclinical disruptions in at least three of the five major domains (amyloid, tau, vascular, immune, metabolic) will progress to AD at higher rates than those with isolated pathology.",
        "Multi-modal biomarker panels (combining imaging, blood, and CSF markers) will outperform any single biomarker in predicting conversion from mild cognitive impairment to AD.",
        "Network-level interventions (e.g., lifestyle changes affecting vascular and metabolic health) will slow progression more than single-target drugs."
    ],
    "new_predictions_unknown": [
        "Interventions that simultaneously target multiple disrupted networks (e.g., anti-amyloid, anti-inflammatory, vascular support, metabolic enhancement) will halt or reverse early AD progression more effectively than single-target therapies.",
        "Novel network-level biomarkers (e.g., connectome-based signatures) will enable pre-symptomatic detection of AD decades before clinical onset."
    ],
    "negative_experiments": [
        "If individuals with only one disrupted domain (e.g., amyloid only) progress to AD at the same rate as those with multi-domain disruption, the theory is challenged.",
        "If single-modality detection methods are found to be as accurate as multi-modal approaches in large, diverse cohorts, the theory is called into question."
    ],
    "unaccounted_for": [
        {
            "text": "Rare familial AD cases with single-gene mutations may not require multi-domain disruption.",
            "uuids": []
        }
    ],
    "conflicting_evidence": [
        {
            "text": "Some individuals with extensive amyloid and tau pathology do not develop dementia (asymptomatic AD).",
            "uuids": []
        }
    ],
    "special_cases": [
        "Familial AD due to deterministic mutations may follow a different, more linear pathogenesis.",
        "Individuals with high cognitive reserve may resist network disruption longer."
    ],
    "existing_theory": {
        "what_already_exists": "Multi-factorial and multi-modal models of AD exist, and the importance of network interactions is increasingly recognized.",
        "what_is_novel": "The explicit requirement for concurrent, interacting disruptions across multiple systems as the primary cause, and the necessity of network-level, integrated detection, is a novel synthesis.",
        "classification_explanation": "This theory builds on and extends existing multi-factorial models by formalizing the necessity of network-level, self-reinforcing interactions and detection.",
        "likely_classification": "somewhat-related-to-existing",
        "references": [
            "De Strooper & Karran (2016) The Cellular Phase of Alzheimer's Disease [Multi-factorial pathogenesis]",
            "Iturria-Medina et al. (2016) Multifactorial causal model of brain (dis)organization and therapeutic intervention: Application to Alzheimer's disease [Network-level modeling]",
            "Jack et al. (2018) NIA-AA Research Framework [Multi-modal biomarker approach]"
        ]
    },
    "reflected_from_theory_index": 0,
    "type": "general",
    "version": "built-theory-from-results-single-theory-reflection2-nov14-2025-LLM-BASELINE-no-evidence-without-matched-control-theory-name",
    "theory_query": "Build a theory of the causes of Alzheimer's disease and effective detection methods.",
    "original_theory_id": "theory-683",
    "original_theory_name": "Peripheral Platelet Tau/AÎ² Signature as a Surrogate for Central Neurodegeneration",
    "provide_matched_control_thery_name": false,
    "matched_control_theory_name": null,
    "model_str": "openai/gpt-4.1-2025-04-14"
}</code></pre>
        </div>
    </div>
</body>
</html>